Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02914639 · ClinicalTrials.gov registry record · Phase 1
Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)
A Phase 1 study of Age-related Macular Degeneration, sponsored by OcuTerra Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 12
- Study locations
NCT02914639 is a Phase 1 study of Age-related Macular Degeneration that has completed, run by OcuTerra Therapeutics. The registered enrollment target is 44 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 8 states.
The verdict
NCT02914639, a Phase 1 study of Age-related Macular Degeneration, has completed, sponsored by OcuTerra Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 12
- Study locations
Study Summary
The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
Conditions Studied
Interventions
- DRUG SF0166 Topical Ophthalmic Solution
Study Locations (12)
Texas
- West Texas Retina Consultants - Abilene
- Retina Research Center, PLLC - Austin
- Texas Retina Associates - Fort Worth
California
- Retina Consultants of Orange County - Fullerton
- Northern California Retina Vitreous Associates Medical Group, Inc - Mountain View
Florida
- Retina Macula Specialists of Miami, LLC - Miami
- Center for Retina and Macular Disease - Winter Haven
Arizona
- Retinal Research Institute LLC - Phoenix
Indiana
- John Kenyon Eye Institute - New Albany
Massachusetts
- Ophthalmic Consultants of Boston - Boston
South Dakota
- Black Hills Regional Eye Institute - Rapid City
Washington
- Spokane Eye Clinical Research - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2016-10-05 |
| Est. Completion | 2017-06-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02914639
The ClinicalTrials.gov registry entry for NCT02914639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (97% lower). The listed sponsor is OcuTerra Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which SF0166 Topical Ophthalmic Solution is the first listed.
NCT02914639 reports 12 study locations spanning 8 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT02914639 about?
NCT02914639 is a clinical study titled "Safety and Exploratory Efficacy Study of SF0166 in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)". The primary purpose of this study was to evaluate the safety and exploratory efficacy of SF0166 Topical Ophthalmic Solution in patients with Neovascular (wet) Age-related Macular Degeneration (AMD).
What is the current status of trial NCT02914639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2016-10-05. Estimated completion is 2017-06-26.
What conditions does trial NCT02914639 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT02914639?
The interventions under investigation include: SF0166 Topical Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT02914639?
This trial is sponsored by OcuTerra Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02914639 being conducted?
This trial has 12 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.